SCHEMBL20516748

SCHEMBL20516748

CC(F)(F)c1ccncc1Br

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.34
IDO1 P14902 1/20 0.34
CA12 O43570 3/20 0.33
CA1 P00915 3/20 0.33
CA2 P00918 3/20 0.33
CA9 Q16790 3/20 0.33
CA14 Q9ULX7 2/20 0.33
CCNC P24863 1/20 0.33
CDK8 P49336 1/20 0.33
TP53 P04637 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP1 P29466 1/20 0.33
BLM P54132 1/20 0.33
CASP7 P55210 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
PTGS1 P23219 3/20 0.32
PTGS2 P35354 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL359606 0.84 NPC1 (0.37) AXLCCNCCDK8ALDH1A1KIF11
SCHEMBL7253767 0.84 ALOX5 (0.39) AXLCA12CA1CA2CA9
SCHEMBL526754 0.81 CCNC (0.36) AXLCA12CA1CA2CA9
SCHEMBL28553770 0.79 AXL (0.38) AXLCCNCCDK8TP53MAPT
SCHEMBL16167559 0.78 KIF11 (0.34) IDO1PTGS1PTGS2ALDH1A1KIF11
SCHEMBL22140201 0.78 TP53 (0.34) AXLCA12CA1CA2CA9
SCHEMBL11710618 0.76 AXL (0.35) AXLCCNCCDK8
SCHEMBL22085299 0.72 LOXL2 (0.48) IDO1CYP3A4
SCHEMBL5700045 0.71 KIF11 (0.37) AXLMAPTSMN1; SMN2ALDH1A1KIF11
SCHEMBL16418926 0.71 KIF11 (0.35) AXLCA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117024411-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2026-05-19 CN disclosed
CN-117024411-A Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2023-11-10 CN disclosed
CN-110709392-B Isoquinoline as HPK1 inhibitor 豪夫迈·罗氏有限公司 2023-09-29 CN disclosed
US-11566003-B2 Isoquinolines as inhibitors of HPK1 GENENTECH, INC. (US) 2023-01-31 US disclosed
EP-3806958-B1 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT JANSSEN PHARMACEUTICA NV (BE) 2022-09-07 EP disclosed
EP-3807261-B1 PYRIDINYL PYRAZOLES AS MODULATORS OF RORYT JANSSEN PHARMACEUTICA NV (BE) 2022-07-13 EP disclosed
EP-3807261-B1 PYRIDINYL PYRAZOLES AS MODULATORS OF RORYT JANSSEN PHARMACEUTICA NV (BE) 2022-07-13 EP disclosed
EP-3601259-B1 ISOQUINOLINES AS INHIBITORS OF HPK1 HOFFMANN LA ROCHE (CH) 2022-02-23 EP disclosed
US-11034658-B2 Pyridinyl pyrazoles as modulators of RORγT JANSSEN PHARMACEUTICA NV (BE) 2021-06-15 US disclosed
US-11034658-B2 Pyridinyl pyrazoles as modulators of RORγT JANSSEN PHARMACEUTICA NV (BE) 2021-06-15 US disclosed
US-10975057-B2 6-aminopyridin-3-yl pyrazoles as modulators of RORgT JANSSEN PHARMACEUTICA NV (BE) 2021-04-13 US disclosed
US-10975057-B2 6-aminopyridin-3-yl pyrazoles as modulators of RORgT JANSSEN PHARMACEUTICA NV (BE) 2021-04-13 US disclosed
CN-112292373-A Pyridylpyrazoles as modulators of ROR γ t 詹森药业有限公司 2021-01-29 CN disclosed
CN-112292183-A 6-aminopyridin-3-yl-pyrazoles as modulators of ROR γ t 詹森药业有限公司 2021-01-29 CN disclosed
CN-110709392-A Isoquinoline as HPK1 inhibitors 豪夫迈·罗氏有限公司 2020-01-17 CN disclosed
WO-2019244002-A1 PYRIDINYL PYRAZOLES AS MODULATORS OF RORYT JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed
WO-2019244002-A1 PYRIDINYL PYRAZOLES AS MODULATORS OF RORYT JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed
WO-2019244001-A1 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed
WO-2019244001-A1 6-AMINOPYRIDIN-3-YL PYRAZOLES AS MODULATORS OF RORYT JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed
US-20180282282-A1 ISOQUINOLINES AS INHIBITORS OF HPK1 GENENTECH, INC. (US) 2018-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11034658-B2 Pyridinyl pyrazoles as modulators of RORγT RORC, RORB, RORA AXL 2397/4885IDO1 217/4885CA12 4786/4885
US-20180282282-A1 ISOQUINOLINES AS INHIBITORS OF HPK1 HIPK1, HPGDS, IP6K1 AXL 4734/4885IDO1 856/4885CA12 4882/4885
US-11566003-B2 Isoquinolines as inhibitors of HPK1 HIPK1, HIPK2, IP6K1 AXL 4640/4885IDO1 944/4885CA12 4885/4885
US-10975057-B2 6-aminopyridin-3-yl pyrazoles as modulators of RORgT RORC, RORA, RORB AXL 3315/4885IDO1 271/4885CA12 4534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.